9 research outputs found
Anti-Biofilm Activity of Phenyllactic Acid against Clinical Isolates of Fluconazole-Resistant Candida albicans
: Commonly found colonizing the human microbiota, Candida albicans is a microorganism known for its ability to cause infections, mainly in the vulvovaginal region, and is responsible for 85% to 90% of vulvovaginal candidiasis (VVC) cases. The development of drug resistance in C. albicans isolates after long-term therapy with fluconazole is an important complication to solve and new therapeutic strategies are required to target this organism and its pathogenicity. In the present study, phenyllactic acid (PLA) an important broad-spectrum antimicrobial compound was investigated for its antifungal and antivirulence activities against clinical isolates of C. albicans. Previously characterized strains of C. albicans isolates from women with VVC and C. albicans ATCC90028 were used to evaluate the antimicrobial and time dependent killing assay activity of PLA showing a MIC 7.5 mg mL-1 and a complete reduction of viable Candida cells detected by killing kinetics after 4 h of treatment with PLA. Additionally, PLA significantly reduced the biomass and the metabolic activity of C. albicans biofilms and impaired biofilm formation also with changes in ERG11, ALS3, and HWP1 genes expression as detected by qPCR. PLA eradicated pre-formed biofilms as showed also with confocal laser scanning microscopy (CLSM) observations. Furthermore, the compound prolonged the survival rate of Galleria mellonella infected by C. albicans isolates. These results indicate that PLA is a promising candidate as novel and safe antifungal agents for the treatment of vulvovaginal candidiasis
Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
SARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19 due to immunosuppression. Anti-SARS-CoV-2 neutralizing antibodies protect against severe COVID-19. This retrospective real-life study aimed to evaluate seropositivity and neutralizing antibody rates against SARS-CoV-2 and its Omicron BA.1 variant in hematological patients. A total of 106 patients with different hematologic malignancies, who have mostly received three or more vaccine doses (73%), were included in this study. Serum was collected between May and June 2022. The primary endpoint was anti-SARS-CoV-2 antibody response against ancestral (wild type; wt) and Omicron BA.1 virus, defined as a neutralizing antibody titer ≥ 1:10. Adequate neutralizing antibody response was observed in 75 (71%) and 87 (82%) of patients for wt and Omicron BA.1 variants, respectively.However, patients with B-cell lymphoproliferative disorders and/or those treated with anti-CD20 monoclonal antibodies in the prior 12 months showed a lower seropositivity rate compared to other patients against both Omicron BA.1 variant (73% vs 91%; P = 0.02) and wt virus (64% vs 78%; P = 0.16). Our real-life experience confirmed that full vaccination against SARS-CoV-2 induces adequate neutralizing antibody protection for both the wt virus and Omicron BA.1 variants, even in hematological frail patients. However, protective measures should be maintained in hematological patients, especially those with B-cell lymphoproliferative diseases treated with anti-CD20 monoclonal antibodies, because these subjects could have a reduced neutralizing antibody production
Supplement: "Localization and broadband follow-up of the gravitational-wave transient GW150914" (2016, ApJL, 826, L13)
This Supplement provides supporting material for Abbott et al. (2016a). We briefly summarize past electromagnetic (EM) follow-up efforts as well as the organization and policy of the current EM follow-up program. We compare the four probability sky maps produced for the gravitational-wave transient GW150914, and provide additional details of the EM follow-up observations that were performed in the different bands
Validation and psychometric properties of the Italian version of the Fear of Guilt Scale
Numerosi studi e osservazioni cliniche hanno dimostrato il ruolo centrale del timore di colpa nella genesi e nel mantenimento del disturbo ossessivo-compulsivo. Ad oggi, in lingua italiana sono disponibili questionari che misurano la propensione a sperimentare il senso di colpa e la sensibilità individuale verso questa emozione, ma nessuno strumento per valutare il timore di colpa e l’impegno a prevenire o neutralizzare questa esperienza. Lo scopo dello studio è di validare la versione italiana della Fear of Guilt Scale (FOGS), uno strumento che aiuterebbe a discriminare il peso di questo specifico fattore nella sintomatologia ossessiva. A tal fine, la FOGS è stata somministrata a due campioni non clinici (Studio 1) e a una popolazione clinica composta da un sottogruppo con diagnosi di Disturbo ossessivo-compulsivo, uno con diagnosi di Disturbo depressivo maggiore e un altro con diagnosi di Disturbo d’ansia (Studio2). Lo Studio 1 ha confermato la struttura originaria a due fattori (Punizione e Prevenzione del Danno) e ha mostrato un’adeguata coerenza interna, validità convergente e divergente della versione italiana della FOGS. Lo studio 2 ha rivelato che la FOGS è in grado di discriminare i pazienti con disturbo ossessivo-compulsivo dagli altri gruppi di controllo clinico e di prevedere la gravità dei sintomi ossessivi. Si discutono le implicazioni cliniche e di ricerca di questi risultati.Several studies and clinical observations have proven the central role of the fear of guilt in the genesis and maintenance of Obsessive-Compulsive Disorder. To date, questionnaires are available in Italian that measure one’s propensity to experience guilt and sensitivity towards this emotion, understood as a tendency to negatively judge this experience and its effects, but not the fear of guilt and the commitment to prevent or neutralise this experience. The purpose of this study is to validate the Italian version of the Fear of Guilt Scale (FOGS), a tool that would facilitate a more comprehensive understanding of the weight of this specific factor in the obsessive symptomatology. To this end, the FOGS was administered to two non-clinical samples (Study 1) and to a clinical population diagnosed with either Obsessive-Compulsive Disorder, Major Depressive Disorder or Anxiety Disorder (Study2). Study 1 confirmed the original two-factors structure (Punishment and Harm Prevention), and showed adequate internal consistency, convergent and divergent validity of the Italian version of the FOGS. Study 2 revealed that the Italian version of the FOGS was able to discriminate between patients with Obsessive-Compulsive Disorder and the other clinical control groups, and in predicting the severity of obsessive symptoms. Clinical and research implications are also discussed
P1531: TIXAGEVIMAB-CILGAVIMAB THERAPY IN THE PREVENTION OF SARS-COV2 INFECTION IN NON-HODGKIN-B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE
Urban air quality comparison for bus, tram, subway and pedestrian commutes in Barcelona
Highlights • Big differences in the aerosols inhaled in bus, subway, tram and walking journeys • Particle number concentration is lowest in subway trains and highest in diesel bus • City centre traffic crossings show particle transient peaks >1×105 part./cm3 • Tram is the cleanest form of city public transport when compared to bus and subway • Subway particles are rich in Fe–Mn, and diesel bus particles are richer in Sb–C
Urban air quality comparison for bus, tram, subway and pedestrian commutes in Barcelona
Access to detailed comparisons in air quality variations encountered when commuting through a city offers the urban traveller more informed choice on how to minimise personal exposure to inhalable pollutants. In this study we report on an experiment designed to compare atmospheric contaminants inhaled during bus, subway train, tram and walking journeys through the city of Barcelona. Average number concentrations of particles 10-300 nm in size, N, are lowest in the commute using subway trains (N4part.cm-3), higher during tram travel and suburban walking (2.5 Ã\u97104cm-34cm-3), and highest in diesel bus or walking in the city centre (N>5.0Ã\u97104cm-3), with extreme transient peaks at busy traffic crossings commonly exceeding 1.0Ã\u97105cm-3 and accompanied by peaks in Black Carbon and CO. Subway particles are coarser (mode 90nm) than in buses, trams or outdoors (2.5) and Black Carbon are lower in the tram when compared to both bus and subway. CO2 levels in public transport reflect passenger numbers, more than tripling from outdoor levels to >1200ppm in crowded buses and trains. There are also striking differences in inhalable particle chemistry depending on the route chosen, ranging from aluminosiliceous at roadsides and near pavement works, ferruginous with enhanced Mn, Co, Zn, Sr and Ba in the subway environment, and higher levels of Sb and Cu inside the bus. We graphically display such chemical variations using a ternary diagram to emphasise how "air quality" in the city involves a consideration of both physical and chemical parameters, and is not simply a question of measuring particle number or mass
Prosafe: a european endeavor to improve quality of critical care medicine in seven countries
BACKGROUND: long-lasting shared research databases are an important source of epidemiological information and can promote comparison between different healthcare services. Here we present ProsaFe, an advanced international research network in intensive care medicine, with the focus on assessing and improving the quality of care. the project involved 343 icUs in seven countries. all patients admitted to the icU were eligible for data collection. MetHoDs: the ProsaFe network collected data using the same electronic case report form translated into the corresponding languages. a complex, multidimensional validation system was implemented to ensure maximum data quality. individual and aggregate reports by country, region, and icU type were prepared annually. a web-based data-sharing system allowed participants to autonomously perform different analyses on both own data and the entire database. RESULTS: The final analysis was restricted to 262 general ICUs and 432,223 adult patients, mostly admitted to Italian units, where a research network had been active since 1991. organization of critical care medicine in the seven countries was relatively similar, in terms of staffing, case mix and procedures, suggesting a common understanding of the role of critical care medicine. conversely, icU equipment differed, and patient outcomes showed wide variations among countries. coNclUsioNs: ProsaFe is a permanent, stable, open access, multilingual database for clinical benchmarking, icU self-evaluation and research within and across countries, which offers a unique opportunity to improve the quality of critical care. its entry into routine clinical practice on a voluntary basis is testimony to the success and viability of the endeavor
Open data from the first and second observing runs of Advanced LIGO and Advanced Virgo
Advanced LIGO and Advanced Virgo are monitoring the sky and collecting gravitational-wave strain data with sufficient sensitivity to detect signals routinely. In this paper we describe the data recorded by these instruments during their first and second observing runs. The main data products are gravitational-wave strain time series sampled at 16384 Hz. The datasets that include this strain measurement can be freely accessed through the Gravitational Wave Open Science Center at http://gw-openscience.org, together with data-quality information essential for the analysis of LIGO and Virgo data, documentation, tutorials, and supporting software